The role of ganciclovir for the management of cytomegalovirus retinitis in HIV patients: Pharmacological review and update on new developments

Canadian Journal of Infectious Diseases

Volumn 7, Issue 3, 1996, Pages 183-194

  Tseng, Alice ^a,b   Foisy, Michelle ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

AIDS; Cytomegalovirus retinitis; Ganciclovir

Indexed keywords

CILASTATIN PLUS IMIPENEM; CYCLOSPORIN; DIDANOSINE; GANCICLOVIR; PROBENECID; ZIDOVUDINE;

BLOOD TOXICITY; CYTOMEGALOVIRUS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG COST; DRUG FORMULATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; RETINITIS; REVIEW; SEIZURE; SEIZURE SUSCEPTIBILITY; TOPICAL DRUG ADMINISTRATION;

EID: 0030015761     PISSN: 11802332     EISSN: None     Source Type: Journal    
DOI: 10.1155/1996/780831     Document Type: Review

References (65)

1. Cytovene Product Monograph. Mississauga: Hoffmann-La Roche, Ltd, 1995.
2. Faulds D, Heel RC. Ganciclovir - a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 1990;39:597-638.
3. Collaborative DHPG Treatment Study Group: treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies. N Engl J Med 1986;314:801-5.
4. Deeter RG, Khanderia U. Recent advances in antiviral therapy. Clin Pharm 1986;5:961-76.
5. Plotkin SA, Drew WL, Felsenstein D, et al. Sensitivities of clinical isolates of human cytomegalovirus to 9-(1,3-dihydroxy-2-propoxymethyl)guanine. J Infect Dis 1985;154:833-4.
6. Shepp DH, Dandliker PS, de Miranda P, et al. Activity of 9-(2-hydroxy-1-(hydroxymethyl)-ethoxymethyl)guanine in the treatment of cytomegalovirus pneumonia. Ann Intern Med 1985;103:368-73.
7. Jabs DA, Wingard JR, de Bustros S, et al. BW B759U for cytomegalovirus retinitis: intraocular drug penetration. Arch Ophthalmol 1986;104:1436-7.
8. Felsenstein D, D'Amico DJ, Hirsch MS, et al. Treatment of cytomegalovirus retinitis with 9-(2-hydroxy-1(hydroxymethyl) ethoxymethyl)guanine. Ann Intern Med 1985;103:377-80.
9. Mar EC, Cheng YC, Huang ES. Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro. Antimicrob Agents Chemother 1983;24:518-21.
10. Tyms AS, Davis JM, Jeffries DJ, et al. BW759U, an analog of acyclovir, inhibits human cytomegalovirus in vitro. Lancet 1984;ii:924-5.
11. Cole ML, Balfour HH Jr. In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to acyclovir and ganciclovir. Diagn Microbiol Infect Dis 1987;6:255-61.
12. Cheng YC, Huang ES, Lin JC, et al. Unique spectrum of activity of 9-((1,3-dihydroxy-2-propoxy)methyl)guanine against herpes viruses in vitro and its mode of action against herpes simplex virus type 1. Proc Natl Acad Sci USA 1983;80:2767-70.
13. Smee DF, Martin JC, Verhayden JPH, et al. Antiherpes activity of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl) guanine. Antimicrob Agents Chemother 1983;23:676-82.
14. Drew WL, Miner RC, Saleh E. Antiviral susceptibility testing of cytomegalovirus: criteria for detecting resistance to antivirals. Clin Diagn Virol 1993;1:179-85.
15. Drew WL. Prevalence and management of CMV resistance. Theory into practice: the role of oral ganciclovir for CMV retinitis and CMV disease. Second National Conference on Human Retroviruses and Related Infections. Washington, January 29 to February 2, 1995.
16. Manischewitz JF, Quinnan GV Jr, Lane HC, et al. Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro. Antimicrob Agents Chemother 1990;34:373-5.
17. Drew WL, Miner RC, Busch DF, et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infections. J Infect Dis 1991;163:716-9.
18. Spector SA, Busch DF, Follansbee S, et al. Pharmacokinetic, safety and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. J Infect Dis 1995;171:1431-7.
19. Anderson RD, Griffy KG, Jung D, et al. Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000 mg/day dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients. Clin Ther 1995;17:425-32.
20. Byrne A, Lavelle J, Follansbee S, et al. Multiple dose crossover pharmacokinetic study to evaluate the effect of food on the relative bioavailability of oral ganciclovir. Eighth International Conference on AIDS. Amsterdam, July 19 to 24, 1992.
21. Morse GD, Shelton MJ, O'Donnell AM. Comparative pharmacokinetics of antiviral nucleoside analogues. Clin Pharmacokinet 1993;24:101-23.
22. Fletcher C, Sawchuk R, Chinnock MT, et al. Human pharmacokinetics of the antiviral drug DHPG. Clin Pharmacol Ther 1986;40:281-6.
23. Arevalo JF, Gonzalez C, Capparelli EV, et al. Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis. J Infect Dis 1995;172:951-6.
24. Kupperman BD, Quiceno JI, Flores-Aguilar M, et al. Intravitreal ganciclovir concentration after intravenous administration for AIDS patients with cytomegalovirus retinitis: implications for therapy. J Infect Dis 1993;168:1506-9.
25. Henry K, Cantrill H, Fletcher C, et al. Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS. Am J Ophthalmol 1987;103:17-23.
26. Laskin OL, Stahl-Bayliss CM, Kalman CM, et al. Use of ganciclovir to treat serious cytomegalovirus infections in patients with AIDS. J Infect Dis 1987;155:323-7.
27. Sommadossi JP, Bevan R, Ling T, et al. Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function. Rev Infect Dis 1988;10(Suppl 3):S507-14.
28. Boulieu R, Bastien O, Bleyzac N. Pharmacokinetics of ganciclovir in heart transplant patients undergoing continuous venovenous hemodialysis. Ther Drug Monit 1993;15:105-7.
29. Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant: a randomized controlled clinical trial. Arch Ophthalmol 1994;112:1531-9.
30. Hochster H, Dieterich D, Bozzette S, et al. Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS: an AIDS clinical trials group study. Ann Intern Med 1990;113:111-7.
31. Gaines K, Wong R, Jung D. Pharmacokinetic interactions with oral ganciclovir: zidovudine, didanosine, probenecid. Tenth International Conference on AIDS. Yokohama, August 1994.
32. Pinching AJ, Helbert M, Peddle B, et al. Clinical experience with zidovudine for patients with acquired immune deficiency syndrome and acquired immune deficiency syndrome-related complex. J Infect 1989;18(Suppl 1):33-40.
33. Frascino RJ, Gaines-Griffy K, Jung D, et al. Multiple dose crossover study of IV ganciclovir induction dose (5 mg/kg IV q12h) and didanosine (100 mg po q12h) in HIV-infected persons. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 17 to 20, 1995.
34. Lake KD. Management of drug interactions with cyclosporine. Pharmacotherapy 1991;11:110S-8S.
35. Freitas VR, Fraser-Smith EB, Matthews TR. Efficacy of ganciclovir in combination with other antimicrobial agents against cytomegalovirus in vitro and in vivo. Antiviral Res 1993;20:1-12.
36. Drew WL. Cytomegalovirus infection in patients with AIDS. Clin Infect Dis 1992;14:608-15.
37. Polis MA. Foscarnet and ganciclovir in the treatment of CMV retinitis. J Acquir Immun Defic Syndr 1992;5(Suppl 1): S3-10.
38. Masur H, Lane HC, Palestine A, et al. Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on serious cytomegalovirus disease in eight immunosuppressed homosexual men. Ann Intern Med 1986;104:41-4.
39. Palestine AG, Stevens G Jr, Lane HC, et al. Treatment of cytomegalovirus retinitis with dihydroxy popoxylmethyl guanine. Am J Ophthalmol 1986;101:95-101.
40. Holland GN, Sidikaro Y, Kreiger AE, et al. Treatment of cytomegalovirus retinopathy with ganciclovir. Ophthalmology 1987;94:815-23.
41. Jabs DA, Newman C, De Bustros S, et al. Treatment of cytomegalovirus retinitis with ganciclovir. Ophthalmology 1987;94:824-30.
42. Holland GN, Buhles WC, Mastre B, et al. A controlled, retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Arch Ophthalmol 1989;107:1759-66.
43. Studies of Ocular Complications of AIDS Research Group, in Collaboration with the AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992;326:213-20.
44. Ussery FM III, Gibson SR, Conklin RH, et al. Intravitreal ganciclovir in the treatment of AIDS-associated CMV retinitis. Ophthalmology 1988;95:640-8.
45. Cantrill HL, Henry K, Melroe NH, et al. Treatment of cytomegalovirus retinitis with intravitreal ganciclovir: long-term results. Ophthalmology 1989;96:367-74.
46. Heinemann M. Long-term intravitreal ganciclovir therapy for cytomegalovirus retinopathy. Arch Ophthalmol 1989;107:1767-72.
47. Chiron Ganciclovir Implant Study Group. A randomized controlled multicenter clinical trial of a sustained-release intraocular ganciclovir implant in AIDS patients with CMV retinitis. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 17 to 20, 1995.
48. Anand R, Font RL, Fish RH, et al. Pathology of cytomegalovirus retinitis treated with sustained release intravitreal ganciclovir. Ophthalmology 1993;100:1032-9.
49. Anand R, Nightingale S, Fish RH, et al. Control of cytomegalovirus retinitis using sustained release of intraocular ganciclovir. Arch Ophthalmol 1993;111:223-7.
50. Drew WL, Ives D, Lalezari JP, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 1995;333:615-20.
51. Squires KE, Stempien MJ, Shadman A, et al. Oral ganciclovir versus intravenous ganciclovir maintenance therapy for cytomegalovirus (CMV) retinitis in patients with AIDS: preliminary results of a phase III study. The First National Conference on Human Retroviruses and Related Infections. Washington, December 12 to 16, 1993.
52. The Oral Ganciclovir European and Australian Cooperative Study Group. Intravenous versus oral ganciclovir: European/Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS. AIDS 1995;9:471-7.
53. Spector SA, McKinley G, Drew WL, et al. A randomized, double-blind study of the efficacy and safety of oral ganciclovir for the prevention of cytomegalovirus disease in HIV-infected persons. Second National Conference on Human Retroviruses and Related Infections. Washington, January 29 to February 2, 1995.
54. Drew WL, Miner RC, Crager M, et al. Prevalence of ganciclovir-resistant cytomegalovirus during oral prophylaxis. 3rd Conference on Retroviruses and Opportunistic Infections. Washington, January 28 to February 1, 1996.
55. Brosgart CL, Craig C, Hillman D, et al, for the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of CMV retinal and gastrointestinal mucosal disease in HIV-infected individuals with severe immunosuppression. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 17 to 20, 1995.
56. Melchior WR, Bindlish V, Rybak MJ. Intravitreal ganciclovir for cytomegalovirus retinitis in AIDS patients. Ann Pharmacother 1992;26:36-7.
57. Ward-Able C, Phillips P, Tsoukas CM. The use of oral ganciclovir in the treatment of cytomegalovirus retinitis in patients with AIDS. Can Med Assoc J 1996;154:363-8.
58. Nelson MR, Barter G, Hawkins D, et al. Simultaneous treatment of cytomegalovirus retinitis with ganciclovir and foscarnet. Lancet 1991;338:250.
59. Butler KM, De Smet MD, Husson RN, et al. Treatment of aggressive cytomegalovirus retinitis with ganciclovir in combination with foscarnet in a child infected with HIV. J Pediatr 1992;120:483-6.
60. Dieterich DT, Poles MA, Lew EA, et al. Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients. J Infect Dis 1993;167:1184-8.
61. Kuppermann BD, Flores-Aguilar M, Quiceno JI, et al. Combination ganciclovir and foscarnet in the treatment of clinically resistant cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. Arch Ophthalmol 1993;111:1359-66.
62. Jabs DA, Studies of Ocular Complications of AIDS Research Group. Combination foscarnet and ganciclovir versus monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS: the Cytomegalovirus Retinitis Retreatment Trial. 3rd Conference on Retroviruses and Opportunistic Infections. Washington, January 28 to February 1, 1996.
63. Grossberg HS, Bonnem EM, Buhles WC Jr. GM-CSF with ganciclovir for the treatment of CMV retinitis in AIDS. N Engl J Med 1989;320:1560. (Lett)
64. Hardy D, Spector S, Posky B, Crumpacker C, et al. Combination of ganciclovir and granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. Eur J Clin Microbiol Infect Dis 1994;(Suppl 2):34-40.
65. Jacobson MA, Stanley HD, Heard SE. Ganciclovir with recombinant methionyl human granulocyte colony-stimulating factor for treatment of cytomegalovirus disease in AIDS patients. AIDS 1992;6:515-6.